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Introduction
Copy number variations (CNVs) are classically defined as large deletions, duplications or inversions of DNA segments of more than 1kb (1) . Recently, researchers have found that multiple CNVs were involved in the development of complex diseases, including cancers (2) (3) (4) . Copy number loss at 11q11 is identified as a potential candidate for colorectal cancer (CRC) susceptibility (5) . And another genome-wide copy number analysis on familial and early-onset CRC has revealed several novel candidate CRC susceptibility genes such as CDH18, GREM1 and BCR (6) . A rare deletion at 12p.12.3 has been observed by Yang R et al. in two of 371 familial CRC cases but none in controls, and the results have been validated in an independent sample (7). Weren RD et al. have detected a rare germline deletion at gene focadhesin (FOCAD) in two of 1232 patients but one in 12 400 controls (P = 0.0067) (8) . They have further suggested that FOCAD might serve as a novel CRC susceptibility gene.
Our previous study has found that the global burden of rare CNVs was significantly increased in CRC cases than controls (9) . Here, we further found deletions at the gene of solute carrier family 18 member A1 (SLC18A1) in four of the 694 CRC cases but none in 1641 cancer-free controls. SLC18A1 is one of the two isoforms of vesicular monoamine transporters, the other one is SLC18A2 (10) . The two transporters are glycoproteins with 12 transmembrane domains and they act to transport monoamines from the cytosol into vesicles, using the proton gradient to create electrochemical gradient across the vesicular membrane (11) . Given the importance of SLC18A1 in the transport of monoamines, variations of SLC18A1 have been associated with some neuropsychiatric disorders, including bipolar disorder, schizophrenia, and some anxiety-related personality traits (12) (13) (14) . In this study, we extensively examined the association between germline deletions affecting SLC18A1 gene and CRC.
Methods

Study population
Our study consisted of an initial discovery cohort from our previous genome-wide association study on CRC and an independent validation cohort, including a total of 1628 CRC patients and 4321 cancer-free controls from China. The discovery cohort was composed of 694 cases and 1641 controls, see details elsewhere (9) . The validation cohort consisted of 934 patients diagnosed with CRC from Zhejiang Cancer Hospital between October 2011 and November 2012. Pathologic diagnoses were determined by pathologists via biopsy reports. All the blood samples for patients were collected at the first diagnosis of CRC before any treatments. 2680 cancer-free subjects in the validation cohort were participants in a large-scale physical examination in the medical center of the Six People's Hospital of Xiaoshan Zhejiang from July 2011 to July 2012. Genomic DNA of blood leukocytes for all included participants was extracted by TACO automatic nucleic acid extraction apparatus (GeneReach Biotechnology Corp., Taiwan, China).
Genomic DNA of CRC tumor and paired normal tissues was extracted from another 96 patients, who were diagnosed with CRC in RunRun Shaw Hospital of Zhejiang University between January 2004 and January 2008. Patient's clinical information was collected from medical records or pathology reports, and the survival data were collected via telephone follow-up.
All the participants signed informed consent forms, and all the study protocols were approved by the ethics committee of School of Medicine, Zhejiang University.
CNV detection and filtering
CNV calling and quality control procedures were described previously (9) . In brief, germline CNVs were identified by Penncnv (15) as well as Quantisnp (16) using intensity data generated by GenomeStudio (Illumina, San Diego, CA). CNV segments identified with the same breakpoints by both PennCNV and QuantiSNP were included for the subsequent filtering. CNVs met the following criteria were excluded: (i) with a Bayes factor <10, (ii) CNVs spanning less than 10 probes, (iii) with length less than 10 kb.
CNV genotyping by TaqMan Copy Number Assay
The copy number states of SLC18A1 were further examined by duplex real-time quantitative polymerase chain reaction using the TaqMan® Copy Number Assays (Applied Biosystems, Foster City, CA). Primers and probes for SLC18A1 (assay ID: Hs01489552_cn) were selected from the pre-designed TaqMan®Copy Number Assay targeting the overlapped region of the four CNVs identified in the discovery stage. The TaqMan® Copy Number Reference Assay, RNase P was selected as internal reference. The assay was carried out according to the manufacturer's protocols on a LightCycler® 480 Instrument (Roche, Mannheim, Germany). The quantitative polymerase chain reaction was performed in 384-well plates with each reaction containing 1 μl of genomic DNA, 5 μl of 2 × LightCycle 480 Probes Master (Roche, Mannheim, Germany), 1/6 μl of 60 × custom copy number assay, 1 μl of 10 × TaqMan Copy Number Reference Assay, and 3 μl of PCR-grade water. Each 384 plate contained four samples with putative two copies of SLC18A1 and a non-template control. All the reactions were conducted in triplicates. The relative copy number of target gene for each individual was estimated based on the '2(-Delta Delta C(T))' method (17) .
Laser capture microdissection and gene expression profiling in three CRC patients
Tumor buddings, cancer cells in the center of primary tumor and normal intestinal epithelial cells were captured using laser capture microdissection (LCM, Thermo Co.). Microdissected cells were stored at −80°C until use. Total RNA extraction was conducted using the PicoPure RNA Isolation Kit (Thermo Co.) according to the manufacturer instructions. The extracted RNA was amplified and assayed using AffymetrixGeneChip® Human Genome U133 Plus 2.0 Array by Shanghai Biotechnology Corporation, China.
Public data
The study included the following datasets of CRC:
1. Dataset with gene expression profile comparing 17 paired CRC and adjacent normal tissue samples were obtained from Gene Expression Omnibus database (accession number: GDS4382) (18) . The dataset was based on the Affymetrix Human GenomeU133 Plus 2.0 Array, and the expression data of the probe corresponding to SLC18A1 (207074_s_at) were extracted. 2. The Cancer Genome Atlas (TCGA) (19) CRC dataset RNA-seq gene expression profiling for CRC tissues (N = 383), clinicopathological variables (N = 548) and follow-up data (N = 506). RNA sequencing data available for both CRC tissues and paired normal tissues were extracted (N = 32). We downloaded clinicopathological variables, follow-up data and germline CNV (level 3) from The TCGA data portal (https://tcga-data.nci.nih.gov/tcga/). Germline CNVs of SLC18A1 were estimated by segment mean ratio. A TCGA pan-cancer dataset of 33 cancer types was obtained, including 7991 samples with available RNA-seq transcriptomes.
Statistical methods
The frequency difference of germline deletions at SLC18A1 between CRC cases and controls was examined by Fisher's exact test. For zero events, we added a fixed value (0.5) to each cell when calculating the odds ratios. Chi-square test was used to assess the association between SLC18A1 expression in CRC tissue and clinicopathological variables. Wilcoxon paired test was applied to compare the mRNA levels of SLC18A1 between primary CRC tissues and the paired adjacent normal tissues. Covariance analysis was utilized to evaluate the expression levels of SLC18A1 among different copy number states adjusting for sex and age. For survival analysis, log-rank tests and multivariate cox-regression analyses adjusted for gender, age and pathological stage were performed. The 25th percentile was used as cut-off point for defining low/high expression levels of SLC18A1. A P value of less than or equal to 0.05 was considered statistically significant. All statistical analyses were carried out using SPSS version 19.0 (SPSS Inc., Chicago, IL) or PLINK (20 
Results
Characteristics of the study subjects
The basic characteristics of the study subjects (including 694 CRC cases and 1641 cancer-free controls after quality control) in the screening stage were described in our previous study (9) . In the replication stage, we genotyped the germline copy number of SLC18A1 in an independent sample consisting of 934 CRC cases and 2680 cancer-free controls (Supplementary Table S1 , available at Carcinogenesis Online). Of the CRC cases, 64.4% were males, and the proportion was significantly higher than cancerfree controls (45.7%) (P < 0.001). The CRC group was significantly older than the control group (P < 0.001).
Germline deletions at SLC18A1 were associated with increased risk of CRC After CNV quality control, we performed gene-based CNV analysis and selected SLC18A1 for replication (see Supplementary Figure S1 , available at Carcinogenesis Online in details). We identified four out of 694 CRC cases were SLC18A1 deletion carriers but none in our cancer-free controls in the discovery stage (Fisher's exact test P = 0.008, Table 1 ). The open reading frame of SLC18A1 was affected in all of the four SLC18A1 deletion carriers ( Figure 1 ). In order to confirm the relationship between germline deletions of SLC18A1 and the risk of CRC, we screened 3614 independent subjects in the replication stage including 934 CRC patients as well as 2680 cancer-free individuals. This screen revealed five additional SLC18A1 deletions in the CRC cases, whereas SLC18A1 deletion was detected in one of the 2680 controls (Fisher's exact test P = 0.005). Combined analysis of all samples from both stages yielded an odds ratio (OR) of 24.0 (Fisher's exact test P = 6.4 × 10 -5 ). The clinical information for all the SLC18A1 deletion carriers was shown in Supplementary 
Down expression of SLC18A1 in CRC tissues
To investigate the differences of SLC18A1 mRNA expression levels between CRC and paired normal tissues, two publicly available datasets from Gene Expression Omnibus and TCGA were used. In TCGA CRC RNA seq dataset, SLC18A1 was significantly down regulated in CRC tissues than in paired normal tissues (N = 32 pairs, P = 0.004, Figure 2A) . Consistently, the expression The number of samples harboring SLC18A1 deletion in each stage. The P values were derived from Fisher's exact test. e We added a fixed value (0.5) to each cell when calculating the odds ratios. levels of SLC18A1 were also found to be significantly decreased in CRC tissue in dataset GDS4382 (N = 17 pairs, P = 0.009, Figure 2B ). In LCM samples, similar observations were obtained that the expression levels of SLC18A1 in the tumor buddings, cancer cells in the center of primary tumor, and stroma of both tumor budding and cancer cells were lower than normal intestinal epithelial and stromal cells (fold change = 0.17-0.62, 0.12-0.57 and 0.37-0.68, respectively, Table 2 ).
Lower expression of SLC18A1 and poor outcome
In TCGA cohort, the lower expression of SLC18A1 was significantly associated with more lymph node metastasis (P = 0.04, Table 3 ). Additionally, patients with lower SLC18A1 expression had shorter overall survival than those with higher SLC18A1 expression (N = 312, log-rank P = 0.043, Figure 3A) . However, the multivariate Cox regression indicated no significant association between SLC18A1 expression and survival after adjusting for gender, age, and tumor-node-metastases (TNM) stage (P = 0.179). A trend of correlation between the expression levels of SLC18A1 and CRC stage was observed but did not reach statistical significance after adjusting by gender and age (N = 298, P = 0.116, Figure  3B ). Patients from pan-cancer dataset with lower expression of SLC18A1 had significantly disadvantage overall survival (P = 2.75 × 10 −10 , Supplementary Figure S2 , available at Carcinogenesis Online).
Discussion
Taken together, our findings strongly showed that a rare deletion at SLC18A1 significantly increased the risk of CRC by a twostage analysis with a combined P value of 6.4 × 10 -5
. Furthermore, SLC18A1 was significantly down regulated in CRC tissues than in paired normal tissues.
In discovery stage, the last six exons of SLC18A1 were disrupted by all the four deletions (Figure 1) . The overlapped region of the four deletions showed an enrichment of enhancer-associated histone mark H3K4me1 in 8 cell lines but was lack of H3K4me3, indicating the region might harbor potential enhancers (21) . Dense potential regulatory elements were also predicted by evolutionary and sequence pattern extraction through reduced representations in the overlapped region (22) . In addition, DNase I hypersensitive clusters and transcription factor binding sites were also marked by the encyclopedia of DNA elements (ENCODE) within the overlapped region, which could be clues about possible regulators of gene expression (23) . All these in silico results exhibited by UCSC genome browser suggested that the region might be a core potential regulation region. Essand M et al. has identified an alternatively spliced form of SLC18A1 lacking exon 15, which lost the key function of biogenic monoamines transportation (24) . They have further proved that CV-1 cells (the cells did not express SLC18A1) transfected with SLC18A1 was significantly down regulated in CRC tissues than paired normal tissues in both datasets (P = 0.004 and P = 0.009, respectively). Ten germline deletions of SLC18A1 were detected in this study, the clinical information for all the SLC18A1 deletion carriers was shown in Supplementary Table S2, available at Carcinogenesis Online. SLC18A1 germline deletion was specific to CRC cases in the screening stage, whereas one deletion was identified in the cancer-free controls in the replication stage. The mean age of diagnosis for the nine CRC cases was 59 but the control carrier was 31 years old. We cannot exclude the possibility that the young control might develop CRC in future.
The expression levels of SLC18A1 were significantly lower in CRC tissues compared with matched normal tissues in TCGA, Gene Expression Omnibus datasets and our LCM samples. Tumor budding is defined as an isolated single cancer cell or a cluster of cancer cells (fewer than five) located at the invasive front of malignancies, which is closely linked with tumor progression (25) . The expression levels of SLC18A1 were lower in tumor buddings compared with that in normal intestinal epithelial cells, implying that SLC18A1 may play roles in the initiation and progression of CRC. Another key factor associated with tumor progression is tumor microenvironment (26, 27) . Increasing evidence suggesting that, tumor development and progression are strongly dependent on interactions between cancer cells and their surrounding microenvironment (28, 29) . The expression levels of SLC18A1 in the stroma components of both tumor budding and cancer cells in cancer center area were lower than that of normal intestinal epithelial cell stroma. These results indicated that the tumor microenvironment of low expression level of SLC18A1 might promote the progress of CRC development.
Of note, we also evaluated the somatic deletions affecting SLC18A1. However, the deletions were resulted from 8p loss, which was common in cancers. The germline deletion affecting SLC18A1 was different from 8p loss. There are several limitations in our present study. Firstly, it should be noted that the exact breakpoints of the germline deletions of SLC18A1 was not determined. Secondly, due to the low expression levels of SLC18A1, we could not precisely detect the expression levels of SLC18A1 via quantitative polymerase chain reaction in our CRC tissues. Finally, we did not detect the protein levels of SLC18A1, the mechanisms of SLC18A1 in initiating or promoting the progression of CRC still remain unknown and require further studies.
In summary, we provided the evidence that rare SLC18A1 germline deletions were significantly associated with increased risk of CRC. We concluded that SLC18A1 might serve as a novel CRC susceptibility gene. Further functional studies are required to determine the role of SLC18A1 in CRC.
Supplementary material
Supplementary Tables S1-S3 and Figures S1 and S2 can be found at https://academic.oup.com/carcin.
